SCHEMBL20138951

SCHEMBL20138951

O=c1[nH]c(-c2cn[nH]c2C(F)(F)F)nc(N2CCOCC2)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 4/20 0.45
PIK3R1 P27986 3/20 0.45
PIK3CG P48736 2/20 0.45
PIK3CA P42336 4/20 0.37
TYMP P19971 1/20 0.37
CDK2 P24941 3/20 0.37
CDC7 O00311 1/20 0.37
CCNE1 P24864 1/20 0.37
ROCK1 Q13464 1/20 0.37
DBF4 Q9UBU7 1/20 0.37
TIPARP Q7Z3E1 1/20 0.37
AKT1 P31749 2/20 0.36
MTOR P42345 1/20 0.36
KMT2A Q03164 1/20 0.36
FLT3 P36888 2/20 0.35
CCNA1 P78396 2/20 0.35
PIK3CB P42338 1/20 0.35
SYK P43405 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20143028 0.84 CDC7 (0.49) PIK3CDPIK3CATYMPCDK2CDC7
SCHEMBL20154205 0.83 ATR (0.47) PIK3CDPIK3R1PIK3CGPIK3CAMTOR
SCHEMBL21531642 0.83 ATR (0.47) PIK3CDPIK3R1PIK3CGPIK3CAMTOR
SCHEMBL20154112 0.81 PIK3CD (0.51) PIK3CDPIK3R1PIK3CGPIK3CACDK2
SCHEMBL20139088 0.79 CDK2 (0.36) PIK3CDPIK3R1PIK3CGPIK3CACDK2
SCHEMBL20154199 0.79 CDK2 (0.39) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL23426250 0.76 IDH1 (0.33) PIK3CDPIK3R1PIK3CGCDK2CDC7
SCHEMBL20138920 0.75 HTR2C (0.35) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL20154198 0.75 HTR2C (0.35) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL20012411 0.72 ALOX5 (0.46) PIK3CATYMPCDK2ROCK1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 US claimed
CN-110088100-B Pyrimidone derivatives as CDC7 inhibitors 癌症研究科技有限公司 2023-02-17 CN claimed
US-20220079942-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2022-03-17 US claimed
US-11020396-B2 Pyrimidinone derivatives as Cdc7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-06-01 US claimed
EP-3538523-B1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2021-05-19 EP claimed
US-20190336502-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-11-07 US claimed
EP-3538523-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS Cancer Research Technology Limited (GB) 2019-09-18 EP claimed
WO-2018087527-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-17 WO claimed
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 US disclosed
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 US disclosed
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 US disclosed
CN-110088100-B Pyrimidone derivatives as CDC7 inhibitors 癌症研究科技有限公司 2023-02-17 CN disclosed
US-20220079942-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2022-03-17 US disclosed
US-11020396-B2 Pyrimidinone derivatives as Cdc7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-06-01 US disclosed
EP-3538523-B1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2021-05-19 EP disclosed
EP-3538523-B1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2021-05-19 EP disclosed
US-20190336502-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-11-07 US disclosed
EP-3538523-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS Cancer Research Technology Limited (GB) 2019-09-18 EP disclosed
WO-2018087527-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-17 WO disclosed
WO-2018087527-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190336502-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CDC7, CDK7, CDK17 PIK3CD 477/4885PIK3R1 1168/4885PIK3CG 752/4885
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CDC7, CDK7, CDK17 PIK3CD 477/4885PIK3R1 1168/4885PIK3CG 752/4885
US-20220079942-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CDC7, CDK7, CDK17 PIK3CD 477/4885PIK3R1 1168/4885PIK3CG 752/4885
US-11020396-B2 Pyrimidinone derivatives as Cdc7 inhibitors CDC7, CDK7, CDK17 PIK3CD 477/4885PIK3R1 1168/4885PIK3CG 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.